TARS – Tarsus Pharmaceuticals Inc
Float Short %
17.95
Margin Of Safety %
Put/Call OI Ratio
0.08
EPS Next Q Diff
0.45
EPS Last/This Y
1.57
EPS This/Next Y
1.53
Price
49.33
Target Price
73.71
Analyst Recom
1.25
Performance Q
20.54
Relative Volume
1.88
Beta
0.81
Ticker: TARS
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | TARS | 54.22 | 4.63 | 0.00 | 3391 |
| 2025-08-18 | TARS | 54.65 | 0.12 | 0.00 | 561 |
| 2025-08-19 | TARS | 53.7 | 0.13 | 0.00 | 566 |
| 2025-08-20 | TARS | 55.46 | 0.12 | 1.59 | 570 |
| 2025-08-21 | TARS | 56.56 | 0.19 | 0.08 | 627 |
| 2025-08-22 | TARS | 57.24 | 0.18 | 0.22 | 678 |
| 2025-08-25 | TARS | 56.64 | 0.16 | 0.00 | 687 |
| 2025-08-26 | TARS | 58.85 | 0.16 | 0.00 | 694 |
| 2025-08-27 | TARS | 57.78 | 0.16 | 0.00 | 692 |
| 2025-08-28 | TARS | 58.12 | 0.16 | 0.13 | 691 |
| 2025-08-29 | TARS | 58.53 | 0.16 | 0.00 | 693 |
| 2025-09-02 | TARS | 58.58 | 0.16 | 0.00 | 695 |
| 2025-09-03 | TARS | 57.7 | 0.16 | 0.00 | 696 |
| 2025-09-04 | TARS | 57.4 | 0.16 | 0.70 | 696 |
| 2025-09-05 | TARS | 57.6 | 0.17 | 0.00 | 682 |
| 2025-09-08 | TARS | 56.65 | 0.09 | 0.10 | 1249 |
| 2025-09-09 | TARS | 56.48 | 0.08 | 0.00 | 1246 |
| 2025-09-10 | TARS | 54.57 | 0.08 | 0.50 | 1267 |
| 2025-09-11 | TARS | 51.88 | 0.08 | 0.26 | 1268 |
| 2025-09-12 | TARS | 49.33 | 0.08 | 0.02 | 1270 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | TARS | 54.21 | 42.6 | - | -1.52 |
| 2025-08-18 | TARS | 54.57 | 42.6 | - | -1.52 |
| 2025-08-19 | TARS | 53.70 | 42.2 | - | -1.50 |
| 2025-08-20 | TARS | 55.47 | 42.2 | - | -1.50 |
| 2025-08-21 | TARS | 56.55 | 42.2 | - | -1.50 |
| 2025-08-22 | TARS | 57.19 | 42.2 | - | -1.50 |
| 2025-08-25 | TARS | 56.63 | 42.2 | - | -1.50 |
| 2025-08-26 | TARS | 58.85 | 42.2 | - | -1.50 |
| 2025-08-28 | TARS | 58.16 | 42.2 | - | -1.50 |
| 2025-08-29 | TARS | 58.58 | 42.2 | - | -1.50 |
| 2025-09-02 | TARS | 58.60 | 42.2 | - | -1.50 |
| 2025-09-03 | TARS | 57.69 | 42.2 | - | -1.50 |
| 2025-09-04 | TARS | 57.40 | 42.2 | - | -1.50 |
| 2025-09-05 | TARS | 57.63 | 42.2 | - | -1.50 |
| 2025-09-08 | TARS | 56.89 | 42.2 | - | -1.50 |
| 2025-09-09 | TARS | 56.49 | 42.2 | - | -1.50 |
| 2025-09-10 | TARS | 54.35 | 42.2 | - | -1.50 |
| 2025-09-11 | TARS | 51.87 | 42.2 | - | -1.50 |
| 2025-09-12 | TARS | 49.33 | 42.2 | - | -1.50 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | TARS | -2.74 | 8.09 | 21.17 |
| 2025-08-18 | TARS | -2.74 | 8.92 | 21.10 |
| 2025-08-19 | TARS | -2.84 | 8.92 | 21.10 |
| 2025-08-20 | TARS | -2.84 | 8.92 | 21.10 |
| 2025-08-21 | TARS | -2.84 | 8.92 | 21.10 |
| 2025-08-22 | TARS | -2.84 | 8.92 | 21.10 |
| 2025-08-25 | TARS | -2.84 | 9.71 | 21.10 |
| 2025-08-26 | TARS | -2.84 | 9.71 | 21.10 |
| 2025-08-27 | TARS | -2.84 | 9.71 | 19.04 |
| 2025-08-28 | TARS | -2.84 | 9.71 | 19.04 |
| 2025-08-29 | TARS | -2.84 | 9.71 | 19.04 |
| 2025-09-02 | TARS | -2.84 | 9.71 | 19.04 |
| 2025-09-03 | TARS | -2.84 | 9.71 | 19.04 |
| 2025-09-04 | TARS | -2.84 | 9.71 | 19.04 |
| 2025-09-05 | TARS | -2.84 | 9.71 | 19.04 |
| 2025-09-08 | TARS | -2.84 | 9.81 | 19.04 |
| 2025-09-09 | TARS | -2.84 | 9.81 | 19.04 |
| 2025-09-10 | TARS | -3.53 | 9.81 | 19.04 |
| 2025-09-11 | TARS | -3.55 | 9.81 | 17.95 |
| 2025-09-12 | TARS | -3.55 | 9.81 | 17.95 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.48
Avg. EPS Est. Current Quarter
-0.35
Avg. EPS Est. Next Quarter
-0.03
Insider Transactions
-3.55
Institutional Transactions
9.81
Beta
0.81
Average Sales Estimate Current Quarter
113
Average Sales Estimate Next Quarter
131
Fair Value
Quality Score
47
Growth Score
55
Sentiment Score
70
Actual DrawDown %
22.5
Max Drawdown 5-Year %
Target Price
73.71
P/E
Forward P/E
50.74
PEG
P/S
7.05
P/B
6.26
P/Free Cash Flow
EPS
-2.33
Average EPS Est. Cur. Y
-1.5
EPS Next Y. (Est.)
0.03
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-31.13
Relative Volume
1.88
Return on Equity vs Sector %
-52.5
Return on Equity vs Industry %
-39.4
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.43
EBIT Estimation
Tarsus Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 323
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
stock quote shares TARS – Tarsus Pharmaceuticals Inc Stock Price stock today
news today TARS – Tarsus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch TARS – Tarsus Pharmaceuticals Inc yahoo finance google finance
stock history TARS – Tarsus Pharmaceuticals Inc invest stock market
stock prices TARS premarket after hours
ticker TARS fair value insiders trading